On the design principles of peptide–drug conjugates for targeted drug delivery to the malignant tumor site

Eirinaios I. Vrettos, Gábor Mező and Andreas G. Tzakos
Beilstein J. Org. Chem. 2018, 14, 930–954. https://doi.org/10.3762/bjoc.14.80

Cite the Following Article

On the design principles of peptide–drug conjugates for targeted drug delivery to the malignant tumor site
Eirinaios I. Vrettos, Gábor Mező and Andreas G. Tzakos
Beilstein J. Org. Chem. 2018, 14, 930–954. https://doi.org/10.3762/bjoc.14.80

How to Cite

Vrettos, E. I.; Mező, G.; Tzakos, A. G. Beilstein J. Org. Chem. 2018, 14, 930–954. doi:10.3762/bjoc.14.80

Download Citation

Citation data can be downloaded as file using the "Download" button or used for copy/paste from the text window below.
Citation data in RIS format can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Zotero.

What file format do you want to export?
What should be included?

Presentation Graphic

Picture with graphical abstract, title and authors for social media postings and presentations.

Citations to This Article

Up to 20 of the most recent references are displayed here.

Scholarly Works

  • Abufara, A.; Mousa, M. A. K.; Nsairat, H. Drug–Drug Conjugates as Intelligent Preclinical Platforms for Targeted Cancer Therapy. Biomolecules 2026, 16, 1417. doi:10.3390/biom16101417
  • Di, M. E.; Di, Y. P. Anticancer Peptides: Design Principles, Translational Bottlenecks, and Emerging Opportunities. Molecules (Basel, Switzerland) 2026, 31, 3319. doi:10.3390/molecules31183319
  • Mallek, W.; Bublewicz, H.; Mirecka, G.; Godziątkowski, K.; Piwkowska, A.; Lesner, A.; Wysocka, M. Guanidinium-rich cell-penetrating peptidomimetic-doxorubicin conjugates show linker-dependent, reduced acute toxicity to cardiomyocytes and normal breast epithelium while retaining activity against a HER2-positive breast cancer model (SKBR3 spheroids). Frontiers in chemistry 2026, 14, 1945333. doi:10.3389/fchem.2026.1945333
  • Shiryaeva, O. S.; Smirnov, E. A.; Znamenskii, V. A.; Murashko, E. A.; Kolobov, A. A.; Bondarenko, A. B.; Korolev, D. V.; Galagudza, M. M.; Cheburkin, Y. V. Synthetic Targeted Peptides in Therapy. Nanobiotechnology Reports 2026, 21, 357–370. doi:10.1134/s2635167626602366
  • Zang, W.; Zhang, Z.; Zhi, Y.; Zhang, W.; Song, F.; Huang, P. Solute carrier family 6 member 14 (SLC6A14): Expression, function, regulation, and impact on tumor progression. Biochemical pharmacology 2026, 251, 118182. doi:10.1016/j.bcp.2026.118182
  • Han, S.; Shin, J.; Kim, J. C.; Na, D. H. Emerging metabolic hormone therapeutics for metabolic dysfunction-associated steatohepatitis: incretin-based drugs, fibroblast growth factor analogs, and liver-targeting strategies. Journal of Pharmaceutical Investigation 2026, 56, 1003–1026. doi:10.1007/s40005-026-00815-4
  • Li, X.; Qian, Y.; Cheng, J.; Chu, Q. Peptides as multifunctional linchpins in targeted drug conjugates. RSC medicinal chemistry 2026, 17, 1794–1810. doi:10.1039/d6md00049e
  • Ouyang, Q.; Wu, G.; Chen, A.; Zhang, R.; Xiao, S.; Guo, D.; Zhang, Q.; Yan, C.; Chen, X.-Z.; Tang, J.; Lyu, H. Peptide Drugs in Gastrointestinal Tumors: Integrating Targeting, Delivery, and Therapeutic Actions for Synergistic Strategies. Biomolecules 2026, 16, 456. doi:10.3390/biom16030456
  • Parang, K.; Do, T.; Dinh, C.; Davani-Davari, D.; Foroughi, M.; Khong, T.; Moazen, M.; Nasrolahi Shirazi, A. Tumor Targeting with Peptide-Drug Conjugates: Showcasing Key Progress and Hurdles. Drug design, development and therapy 2026, 20, 562135–30. doi:10.2147/dddt.s562135
  • Aleem, A. R.; Ali, A.; Ali, W.; Cheng, Y.; Yan, Z.; Xia, C.; Liu, C.; Fu, C.; Hu, Y.; Wang, X. Targeting Tumor Dormancy and Recurrence: Molecular Mechanisms and Peptide Therapeutic Delivery. MedComm – Oncology 2026, 5. doi:10.1002/mog2.70050
  • Li, T.; Yin, J.; Hao, Y.; Gao, W.; Li, Q.; Feng, Q.; Tao, B.; Hao, M.; Liu, Y.; Lin, C.; Wang, D. Single-cell sequencing and organoids: applications in organ development and disease. Molecular biomedicine 2025, 6, 134. doi:10.1186/s43556-025-00364-6
  • Belletto, D.; Cova, T. F. G. G.; Mazzone, G.; Pais, A. A. C. C.; Sicilia, E. Investigation of simvastatin and fluvastatin permeation across cell membrane models using molecular dynamics simulations. The Journal of chemical physics 2025, 163. doi:10.1063/5.0280981
  • Zhang, C.; Zhong, H.; Li, X.; Xing, Z.; Li, S.; Yu, R.; Deng, X. DiWB-1: A Luteinizing Hormone Releasing Hormone (LHRH)-Targeted Peptide-Drug Conjugate (PDC) With Enhanced Tumor Selectivity and PI3K Inhibition Efficacy. Archiv der Pharmazie 2025, 358, e70021. doi:10.1002/ardp.70021
  • Jannati, S.; Patel, A.; Patnaik, R.; Banerjee, Y. Oleocanthal as a Multifunctional Anti-Cancer Agent: Mechanistic Insights, Advanced Delivery Strategies, and Synergies for Precision Oncology. International journal of molecular sciences 2025, 26, 5521. doi:10.3390/ijms26125521
  • Shen, L. doi:10.1002/9781394300150.ch3
  • Jadhav, K.; Abhang, A.; Kole, E. B.; Gadade, D.; Dusane, A.; Iyer, A.; Sharma, A.; Rout, S. K.; Gholap, A. D.; Naik, J.; Verma, R. K.; Rojekar, S. Peptide-Drug Conjugates as Next-Generation Therapeutics: Exploring the Potential and Clinical Progress. Bioengineering (Basel, Switzerland) 2025, 12, 481. doi:10.3390/bioengineering12050481
  • Xiao, W.; Jiang, W.; Chen, Z.; Huang, Y.; Mao, J.; Zheng, W.; Hu, Y.; Shi, J. Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines. Signal transduction and targeted therapy 2025, 10, 74. doi:10.1038/s41392-024-02107-5
  • Zhang, D.-E.; He, T.; Shi, T.; Huang, K.; Peng, A. Trends in the research and development of peptide drug conjugates: artificial intelligence aided design. Frontiers in pharmacology 2025, 16, 1553853. doi:10.3389/fphar.2025.1553853
  • Das, T. N.; Ramesh, A.; Ghosh, A.; Moyra, S.; Maji, T. K.; Ghosh, G. Peptide-based nanomaterials and their diverse applications. Nanoscale horizons 2025, 10, 279–313. doi:10.1039/d4nh00371c
  • Chavda, V. P.; Joshi, D. Surface modified proteins and peptides for targeted drug delivery. Progress in molecular biology and translational science 2025, 212, 389–438. doi:10.1016/bs.pmbts.2024.12.001

Patents

  • ZAHID MALIHA. Lung-specific targeting-peptide (LTP), compositions, and uses thereof. US 12673972 B2, July 7, 2026.
  • LI CHUN; XIONG CHIYI; WEN YUNFEI; SOOD ANIL. Therapeutic peptides. US 12448425 B2, Oct 21, 2025.
  • MARSHALL DANIEL RICHARD; CSENGERY JOHANNA MARIE; MAGUIRE ROBERT JOHN; VOLKMANN ROBERT A. Peptide conjugates of cytotoxins as therapeutics. US 12410262 B2, Sept 9, 2025.
  • WANG XIAOXIAO; LIN MU; ZHANG MEIHONG; ZHANG WEI; WU JUN; ZHANG BOWEN; MA RUIPENG; SUN QI; ZHOU LIANG; WANG DI. SELECTIVE DRUG RELEASE FROM CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS. WO 2025098391 A1, May 15, 2025.
  • MARSHALL DANIEL RICHARD; CSENGERY JOHANNA MARIE; MAGUIRE ROBERT JOHN; VOLKMANN ROBERT A. Peptide conjugates of microtubule-targeting agents as therapeutics. US 12234212 B2, Feb 25, 2025.
  • QI YUNKUN; MENG MING; DU SHANSHAN; YU QIANYAO; YAO JINGFANG. [Tyr3] Octreoate-D-configuration oncolytic peptide conjugate, and preparation method and application of fluorescent probe of [Tyr3] Octreoate-D-configuration oncolytic peptide conjugate. CN 119331056 A, Jan 21, 2025.
  • ZHAO JIAN; ZHU YUNFEI; CHEN MI. Somatostatin subtype-2 receptor (SST2R) targeted therapeutics and uses thereof. US 12134610 B2, Nov 5, 2024.
  • MARSHALL DANIEL RICHARD; CSENGERY JOHANNA MARIE; MAGUIRE ROBERT JOHN; VOLKMANN ROBERT A. Peptide conjugates of cytotoxins as therapeutics. US 11634508 B2, April 25, 2023.
  • MARSHALL DANIEL RICHARD; CSENGERY JOHANNA MARIE; MAGUIRE ROBERT JOHN; VOLKMANN ROBERT A. Peptide conjugates of microtubule-targeting agents as therapeutics. US 11555019 B2, Jan 17, 2023.
  • MAGUIRE ROBERT JOHN; CSENGERY JOHANNA MARIE. PEPTIDE CONJUGATES OF THERAPEUTICS. WO 2022155172 A1, July 21, 2022.
  • MAGUIRE ROBERT JOHN; VAN VLIET MICHIEL CHRISTIAN ALEXANDER; SCHOEVAART WILLEM ROBERT KLAAS. PROCESS FOR PREPARING A CONJUGATE LINKING MOIETY. WO 2022150596 A1, July 14, 2022.